CL2017002679A1 - Inhibidores de bromodominio - Google Patents
Inhibidores de bromodominioInfo
- Publication number
- CL2017002679A1 CL2017002679A1 CL2017002679A CL2017002679A CL2017002679A1 CL 2017002679 A1 CL2017002679 A1 CL 2017002679A1 CL 2017002679 A CL2017002679 A CL 2017002679A CL 2017002679 A CL2017002679 A CL 2017002679A CL 2017002679 A1 CL2017002679 A1 CL 2017002679A1
- Authority
- CL
- Chile
- Prior art keywords
- methylisoquinolin
- methylsulfonylphenyl
- cyclopropylmethoxy
- bromodomain
- polymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>Se describe aquí el inhibidor de bromodominio 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona, que incluye formas cristalinas, formas amorfas, solvatos e hidratos de los mismos, así como composiciones farmacéuticas que incluyen este inhibidor de bromodominio. En algunas realizaciones, la composición farmacéutica comprende 4-[2-(ciclopropilmetoxi)-5- metilsulfonilfenil]-2-metilisoquinolin-1-ona que se ha procesado por micronización o dispersión secada por pulverización. En algunas realizaciones, la composición farmacéutica comprende además al menos un polímero. En algunas realizaciones, las composiciones farmacéuticas comprenden una matriz polimérica sólida que comprende 4-[2-(ciclopropilmetoxi)-5- metilsulfonilfenil]-2-metilisoquinolin-1-ona y al menos un polímero. Las composiciones farmacéuticas que comprenden 4-[2- (ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona son útiles para el tratamiento del cáncer o enfermedad neoplásica.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151205P | 2015-04-22 | 2015-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002679A1 true CL2017002679A1 (es) | 2018-05-25 |
Family
ID=57143581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002679A CL2017002679A1 (es) | 2015-04-22 | 2017-10-20 | Inhibidores de bromodominio |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20160310423A1 (es) |
| EP (1) | EP3285770A4 (es) |
| JP (1) | JP2018513863A (es) |
| KR (1) | KR20170139119A (es) |
| CN (1) | CN107613981A (es) |
| AR (1) | AR104340A1 (es) |
| AU (1) | AU2016252992A1 (es) |
| BR (1) | BR112017022691A2 (es) |
| CA (1) | CA2983446C (es) |
| CL (1) | CL2017002679A1 (es) |
| CO (1) | CO2017011482A2 (es) |
| EA (1) | EA201792317A1 (es) |
| EC (1) | ECSP17071545A (es) |
| HK (1) | HK1243948A1 (es) |
| IL (1) | IL255120B (es) |
| MX (2) | MX390077B (es) |
| PE (1) | PE20180036A1 (es) |
| PH (1) | PH12017501933A1 (es) |
| SG (1) | SG11201708627TA (es) |
| TW (1) | TW201642860A (es) |
| WO (1) | WO2016172618A1 (es) |
| ZA (1) | ZA201707186B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| JP7129973B2 (ja) * | 2016-10-20 | 2022-09-02 | セルジーン クオンティセル リサーチ，インク． | ブロモドメイン阻害剤 |
| KR102587839B1 (ko) | 2016-10-27 | 2023-10-11 | 셀젠 콴티셀 리서치, 인크. | 브로모도메인 및 엑스트라-말단 단백질 억제제 병용 치료요법 |
| JP7434274B2 (ja) * | 2018-07-23 | 2024-02-20 | セルジーン・クオンティセル・リサーチ・インコーポレイテッド | ブロモドメイン阻害剤の合成方法 |
| EP4294397A1 (en) * | 2021-02-22 | 2023-12-27 | Celgene Quanticel Research, Inc. | Bromodomain (bet) inhibitor for use in treating prostate cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| PE20161065A1 (es) * | 2013-10-18 | 2016-11-19 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| JP7129973B2 (ja) * | 2016-10-20 | 2022-09-02 | セルジーン クオンティセル リサーチ，インク． | ブロモドメイン阻害剤 |
-
2016
- 2016-04-19 TW TW105112168A patent/TW201642860A/zh unknown
- 2016-04-21 AR ARP160101100A patent/AR104340A1/es unknown
- 2016-04-22 CN CN201680032770.1A patent/CN107613981A/zh active Pending
- 2016-04-22 CA CA2983446A patent/CA2983446C/en active Active
- 2016-04-22 WO PCT/US2016/029029 patent/WO2016172618A1/en not_active Ceased
- 2016-04-22 MX MX2020010899A patent/MX390077B/es unknown
- 2016-04-22 EP EP16784024.8A patent/EP3285770A4/en not_active Withdrawn
- 2016-04-22 AU AU2016252992A patent/AU2016252992A1/en not_active Abandoned
- 2016-04-22 US US15/136,761 patent/US20160310423A1/en not_active Abandoned
- 2016-04-22 EA EA201792317A patent/EA201792317A1/ru unknown
- 2016-04-22 HK HK18103550.6A patent/HK1243948A1/zh unknown
- 2016-04-22 JP JP2017554566A patent/JP2018513863A/ja active Pending
- 2016-04-22 KR KR1020177033575A patent/KR20170139119A/ko active Pending
- 2016-04-22 MX MX2017013501A patent/MX377159B/es active IP Right Grant
- 2016-04-22 SG SG11201708627TA patent/SG11201708627TA/en unknown
- 2016-04-22 BR BR112017022691-0A patent/BR112017022691A2/pt not_active Application Discontinuation
- 2016-04-22 PE PE2017002306A patent/PE20180036A1/es not_active Application Discontinuation
-
2017
- 2017-10-18 IL IL255120A patent/IL255120B/en active IP Right Grant
- 2017-10-20 CL CL2017002679A patent/CL2017002679A1/es unknown
- 2017-10-23 ZA ZA2017/07186A patent/ZA201707186B/en unknown
- 2017-10-23 PH PH12017501933A patent/PH12017501933A1/en unknown
- 2017-10-26 EC ECIEPI201771545A patent/ECSP17071545A/es unknown
- 2017-11-08 CO CONC2017/0011482A patent/CO2017011482A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201642860A (zh) | 2016-12-16 |
| CN107613981A (zh) | 2018-01-19 |
| EP3285770A1 (en) | 2018-02-28 |
| BR112017022691A2 (pt) | 2018-07-17 |
| PE20180036A1 (es) | 2018-01-09 |
| AU2016252992A1 (en) | 2017-11-09 |
| IL255120B (en) | 2021-03-25 |
| MX390077B (es) | 2025-03-20 |
| ZA201707186B (en) | 2019-01-30 |
| IL255120A0 (en) | 2017-12-31 |
| WO2016172618A1 (en) | 2016-10-27 |
| ECSP17071545A (es) | 2017-12-01 |
| NZ736630A (en) | 2024-03-22 |
| MX377159B (es) | 2025-03-07 |
| MX2017013501A (es) | 2018-02-09 |
| CA2983446C (en) | 2024-04-09 |
| JP2018513863A (ja) | 2018-05-31 |
| EA201792317A1 (ru) | 2018-03-30 |
| MX2020010899A (es) | 2022-02-15 |
| CO2017011482A2 (es) | 2018-01-31 |
| PH12017501933A1 (en) | 2018-03-19 |
| AR104340A1 (es) | 2017-07-12 |
| SG11201708627TA (en) | 2017-11-29 |
| CA2983446A1 (en) | 2016-10-27 |
| EP3285770A4 (en) | 2018-10-31 |
| HK1243948A1 (zh) | 2018-07-27 |
| US20160310423A1 (en) | 2016-10-27 |
| KR20170139119A (ko) | 2017-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002679A1 (es) | Inhibidores de bromodominio | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| CL2019001714A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer. | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| UY37098A (es) | Moduladores de ror-gamma | |
| CL2018003135A1 (es) | Derivados aromáticos de sulfonamida. | |
| CO2019011546A2 (es) | Compuestos y métodos para el tratamiento de enfermedades parasitarias | |
| CL2016003398A1 (es) | Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo. | |
| CU20170089A7 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| NI201700011A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
| CL2016002877A1 (es) | Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos. | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| MX382671B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| CL2016002169A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados. | |
| CL2017000979A1 (es) | Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina | |
| UY36709A (es) | Moduladores de ror gamma (ror¿) | |
| MX2017011655A (es) | Compuestos de aza-piridona y usos de estos. | |
| AR105478A1 (es) | Grados líquidos y sólidos fundibles de peróxidos protegidos por quemadura | |
| SV2016005293A (es) | Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2 | |
| AR109859A1 (es) | Inhibidor de bromodominio | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| CU20190002A7 (es) | Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1 para el tratamiento del cáncer y composiciones farmacéuticas que los comprenden | |
| CL2017001602A1 (es) | Derivados de fumagilol. | |
| PY1749400A (es) | Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos |